Can CDK4/6 inhibitors cause fatal lung injury?

被引：36
|
作者：
Jazieh, Khalid A. [1 ]
Budd, G. Thomas [2 ]
Dalpiaz, Nancy [2 ]
Abraham, Jame [2 ]
机构：
[1] Cleveland Clin Fdn, Dept Internal Med, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Taussig Canc Ctr, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2019年 / 19卷 / 11期
关键词：
Breast Cancer; Palbociclib; Abemaciclib; Pneumonitis; Toxicity; PALBOCICLIB; PNEUMONITIS; CANCER; RISK;
D O I：
10.1080/14737140.2019.1674651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：917 / 919
页数：3
相关论文
共 50 条
  • [21] CDK4/6 inhibitors in luminal breast cancer
    Gnant, Michael
    Steger, Guenther G.
    Bartsch, Rupert
    LANCET ONCOLOGY, 2015, 16 (01): : 2 - 3
  • [22] CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
    Garutti, Mattia
    Targato, Giada
    Buriolla, Silvia
    Palmero, Lorenza
    Minisini, Alessandro Marco
    Puglisi, Fabio
    CELLS, 2021, 10 (06)
  • [23] CDK4/6 Inhibitors: What Is the Best Cocktail?
    Malumbres, Marcos
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 6 - 8
  • [24] Treating cancer with selective CDK4/6 inhibitors
    O'Leary, Ben
    Finn, Richard S.
    Turner, Nicholas C.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) : 417 - 430
  • [25] CDK4/6 inhibitors: taking the place of chemotherapy?
    Nasrazadani, Azadeh
    Brufsky, Adam M.
    LANCET ONCOLOGY, 2019, 20 (10): : 1329 - 1330
  • [26] Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
    Wildey, Gary
    Shay, Ashley M.
    McColl, Karen S.
    Yoon, Suzy
    Shatat, Mohammad A.
    Perwez, Ahmad
    Spainhower, Kyle B.
    Kresak, Adam M.
    Lipka, MaryBeth
    Yang, Michael
    Behtaj, Mohadese
    Fu, Pingfu
    Alahmadi, Asrar
    Mneimneh, Wadad
    Abbas, Ata
    Dowlati, Afshin
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (02) : 264 - 273
  • [27] The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6
    Burke, Teresa
    Torres, Raquel
    McNulty, Ann
    Dempsey, Jack
    Kolis, Stanley
    Kulanthaivel, Palaniappan
    Beckmann, Richard
    CANCER RESEARCH, 2016, 76
  • [28] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
    Zhang, Jinmeng
    Xu, Dayu
    Zhou, Yue
    Zhu, Zhengfei
    Yang, Xi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] Improving Breast Cancer Therapy With CDK4/6 Inhibitors
    Jaganathan, Hamsa
    Overstreet, Karen
    Reed, Elizabeth
    CLINICAL BREAST CANCER, 2014, 14 (06) : 379 - 380
12345